Jelena Kornej

Jelena Kornej

Auto-generated profile, based on publicly available information

Jelena Kornej

Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study Framingham, MA United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Circulation Research
Verified
Journal Article
Closed access
PDF file
JKJelena Kornej
Jelena Kornej
CBChristin S. Börschel
Christin S. Börschel
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
RSRenate B. Schnabel
Renate B. Schnabel
Accompanying the aging of populations worldwide, and increased survival with chronic diseases, the incidence and prevalence of atrial fibrillation (AF) are rising, justifying the term global epidemic. This multifactorial arrhythmia is intertwined with common concomitant cardiovascular diseases, which share classical cardiovascular risk factors. Targeted prevention programs are largely missing. Prevention needs to start at an early age with primordial interventions at the population level. The public health dimension of AF motivates research in modifiable AF risk factors and improved precision in AF prediction and management. In this review, we summarize current knowledge in an attempt to untangle these multifaceted associations from an epidemiological perspective. We discuss disease trends, preventive opportunities offered by underlying risk factors and concomitant disorders, current developments in diagnosis and risk prediction, and prognostic implications of AF and its complications. Finally, we review current technological (eg, eHealth) and methodological (artificial intelligence) advances and their relevance for future prevention and disease management.

17 April 2015 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
JKJelena Kornej
Jelena Kornej
GHGerhard Hindricks
Gerhard Hindricks
MSM. Benjamin Shoemaker
M. Benjamin Shoemaker
DHDaniela Husser
Daniela Husser
AAArash Arya
Arash Arya
ABAndreas Bollmann
Andreas Bollmann

2 June 2021 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
UEUtibe R. Essien
Utibe R. Essien
JKJelena Kornej
Jelena Kornej
AJAmber E. Johnson
Amber E. Johnson
LSLucy B. Schulson
Lucy B. Schulson
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
JMJared W Magnani
Jared W Magnani

30 September 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
JRJason D. Roberts
Jason D. Roberts
EVEric Vittinghoff
Eric Vittinghoff
ALAke T. Lu
Ake T. Lu
AAAlvaro Alonso
Alvaro Alonso
BWBiqi Wang
Biqi Wang
GMGregory M. Marcus
Gregory M. Marcus
Background: The most prominent risk factor for atrial fibrillation (AF) is chronological age; however, underlying mechanisms are unexplained. Algorithms using epigenetic modifications to the human genome effectively predict chronological age. Chronological and epigenetic predicted ages may diverge in a phenomenon referred to as epigenetic age acceleration (EAA), which may reflect accelerated biological aging. We sought to evaluate for associations between epigenetic age measures and incident AF. Methods: Measures for 4 epigenetic clocks (Horvath, Hannum, DNA methylation [DNAm] PhenoAge, and DNAm GrimAge) and an epigenetic predictor of PAI-1 (plasminogen activator inhibitor-1) levels (ie, DNAm PAI-1) were determined for study participants from 3 population-based cohort studies. Cox models evaluated for associations with incident AF and results were combined via random-effects meta-analyses. Two-sample summary-level Mendelian randomization analyses evaluated for associations between genetic instruments of the EAA measures and AF. Results: Among 5600 participants (mean age, 65.5 years; female, 60.1%; Black, 50.7%), there were 905 incident AF cases during a mean follow-up of 12.9 years. Unadjusted analyses revealed all 4 epigenetic clocks and the DNAm PAI-1 predictor were associated with statistically significant higher hazards of incident AF, though the magnitudes of their point estimates were smaller relative to the associations observed for chronological age. The pooled EAA estimates for each epigenetic measure, with the exception of Horvath EAA, were associated with incident AF in models adjusted for chronological age, race, sex, and smoking variables. After multivariable adjustment for additional known AF risk factors that could also potentially function as mediators, pooled EAA measures for 2 clocks remained statistically significant. Five-year increases in EAA measures for DNAm GrimAge and DNAm PhenoAge were associated with 19% (adjusted hazard ratio [HR], 1.19 [95% CI, 1.09–1.31]; P <0.01) and 15% (adjusted HR, 1.15 [95% CI, 1.05–1.25]; P <0.01) higher hazards of incident AF, respectively. Mendelian randomization analyses for the 5 EAA measures did not reveal statistically significant associations with AF. Conclusions: Our study identified adjusted associations between EAA measures and incident AF, suggesting that biological aging plays an important role independent of chronological age, though a potential underlying causal relationship remains unclear. These aging processes may be modifiable and not constrained by the immutable factor of time.

1 April 2014 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
JKJelena Kornej
Jelena Kornej
GHGerhard Hindricks
Gerhard Hindricks
JKJedrzej Kosiuk
Jedrzej Kosiuk
AAArash Arya
Arash Arya
PSPhilipp Sommer
Philipp Sommer
ABAndreas Bollmann
Andreas Bollmann
Background—: Recurrences of atrial fibrillation (AF) occur in up to 30% within 1 year after catheter ablation. This study evaluated the value of CHADS 2 , R 2 CHADS 2 , and CHA 2 DS 2 -VASc scores for the prediction of rhythm outcomes after AF catheter ablation. Methods and Results—: Using the Leipzig Heart Center AF Ablation Registry, we documented rhythm outcomes within the first 12 months in 2069 patients (67% men; 60±10 years; 35% persistent AF) undergoing AF catheter ablation. AF recurrences were defined as any atrial arrhythmia occurring within the first week (early recurrences, ERAF) and between 3 and 12 months (late recurrences, LRAF) after ablation. ERAF and LRAF occurred in 36% and 33%, respectively. On multivariable analysis, R 2 CHADS 2 (odds ratio [OR], 1.11; 95% confidence interval [CI], 1.02–1.21; P =0.016) and CHA 2 DS 2 -VASc (OR, 1.09; 95% CI, 1.017–1.17; P =0.015) scores as well as persistent AF and left atrial diameter were significant predictors for ERAF. Similarly, the same clinical variables remained significant predictors for LRAF even after adjustment for ERAF, which was the strongest predictor for LRAF (HR, 3.12; 95% CI, 2.62–3.71; P <0.001). However, using receiver operating characteristic curve analyses, both scores demonstrated relatively low predictive value for ERAF (area under the curve [AUC], 0.536 [0.510–0.563]; P =0.007; and AUC, 0.547 [0.521–0.573]; P <0.001 for R 2 CHADS 2 and CHA 2 DS 2 -VASc, respectively) and LRAF (AUC, 0.548 [0.518–0.578]; P =0.002; and AUC, 0.550 [0.520–0.580]; P =0.001). Conclusions—: R 2 CHADS 2 and CHA 2 DS 2 -VASc were associated with rhythm outcomes after catheter ablation. However, AF type, left atrial diameter, and especially ERAF are also significant predictors for LRAF that should be included into new clinical scores for the prediction of rhythm outcomes after catheter ablation.

17 April 2023 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
TFTanja Charlotte Frederiksen
Tanja Charlotte Frederiksen
CDChristina C Dahm
Christina C Dahm
SPSarah R. Preis
Sarah R. Preis
HLHonghuang Lin
Honghuang Lin
LTLudovic Trinquart
Ludovic Trinquart
JKJelena Kornej
Jelena Kornej